Back to top
more

Arcturus Therapeutics Holdings (ARCT)

(Delayed Data from NSDQ)

$18.00 USD

18.00
317,940

+0.27 (1.52%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $18.17 +0.17 (0.94%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Arcturus Therapeutics (ARCT) Upgraded to Buy: What Does It Mean for the Stock?

by Zacks Equity Research

Arcturus Therapeutics (ARCT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

ARCT Stock Up as Updated COVID-19 Jab Betters PFE & BNTX's Comirnaty

by Zacks Equity Research

Arcturus stock gains as the company reports that its sa-mRNA COVID-19 vaccine, ARCT-154, shows superior efficacy compared with treatment with Comirnaty.

Here's Why Investors Should Invest in Arcturus Stock Now

by Zacks Equity Research

Here, we are discussing some reasons why investing in ARCT stock now may turn out to be a prudent move.

New Strong Buy Stocks for September 13th

by Zacks Equity Research

ARCT, MHO, FMBH, PAM and ANGO have been added to the Zacks Rank #1 (Strong Buy) List on September 13, 2024.

BioMarin Posts '27 Biz View, Outlines Growth Plans for Next 10 Years

by Zacks Equity Research

BMRN divulges ambitious plans for business growth over the next 10 years. It expects yearly sales to grow at a mid-teen rate through 2034.

Does Arcturus Therapeutics (ARCT) Have the Potential to Rally 216.35% as Wall Street Analysts Expect?

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 216.4% in Arcturus Therapeutics (ARCT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

SNY's MS Drug Meets Goal in One Phase III Study; Misses in Two Others

by Zacks Equity Research

Sanofi's HERCULES phase III study on tolebrutinib meets primary endpoint, showing an improvement in delaying time to onset of confirmed disability progression.

Rhythm Stock Up as FDA Accepts Obesity Drug sNDA for Younger Kids

by Zacks Equity Research

RYTM gains 8% as FDA accepts Imcivree sNDA seeking label expansion of the drug to treat obesity in kids as young as two years old.

AstraZeneca (AZN) Denies Rumors About UK Facility Relocation

by Zacks Equity Research

Per third-party reports, AstraZeneca (AZN) has refuted rumors about considering a change in the relocation of a vaccine manufacturing plant from the U.K. to the United States.

Sutro Biopharma (STRO) Rises 9% in the Past Week: Here's Why

by Zacks Equity Research

Sutro Biopharma (STRO) gains 9% in a week after initiating a phase II study on its lead candidate, luvelta, to treat FRa-expressing lung cancer.

Here's Why You Should Consider Buying Akebia (AKBA) Stock

by Zacks Equity Research

Here, we discuss some reasons why buying Akebia (AKBA) stock now may turn out to be a prudent move.

J&J (JNJ) Gets EU Approval for Bladder Cancer Drug Balversa

by Zacks Equity Research

The approval of J&J's (JNJ) Balversa (erdafitinib) for treating unresectable or metastatic urothelial carcinoma is based on data from the phase III THOR study.

What Makes Arcturus Therapeutics (ARCT) a New Strong Buy Stock

by Zacks Equity Research

Arcturus Therapeutics (ARCT) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Galapagos (GLPG) Up on FDA Nod to Begin Phase I/II Lymphoma Study

by Zacks Equity Research

Galapagos (GLPG) rises in pre-market hours on Aug 23, after the FDA nod to begin early to mid-stage study of GLPG5101 for non-Hodgkin lymphoma patients.

New Strong Buy Stocks for August 23rd

by Zacks Equity Research

RHHBY, SBSI, FCCO, APELY and ARCT have been added to the Zacks Rank #1 (Strong Buy) List on August 23, 2024.

Why Grifols (GRFS) Stock Price Moved Up 7% on Wednesday

by Zacks Equity Research

A Bloomberg article suggests that Brookfield Asset Management is in discussions with banks to raise nearly $11 billion to fund the takeover of Spain-based Grifols (GRFS).

Bristol Myers' (BMY) HCC Combo Drug Accepted for FDA Review

by Zacks Equity Research

Bristol Myers' (BMY) application seeking approval for the Opdivo/Yervoy combo to treat unresectable hepatocellular carcinoma gets accepted for FDA review.

Dr. Reddy's (RDY), Kainomyx Sign Potential Deal for Malaria Drug

by Zacks Equity Research

Dr. Reddy's (RDY) is gearing up to potentially collaborate with Kainomyx to jointly develop an affordable anti-malarial drug.

Xenon (XENE) Focuses on Neuro Candidate Amid Pipeline Woe

by Zacks Equity Research

Xenon's (XENE) clinical studies of azetukalner in epilepsy and other neurological disorders are progressing well. However, any setback is set to hurt the stock in the absence of a deep pipeline.

J&J (JNJ) Gets FDA Nod for Chemotherapy-Free Lung Cancer Therapy

by Zacks Equity Research

The approval is based on late-stage study data wherein treatment with J&J's (JNJ) Rybrevant plus Lazcluze cut the risk of disease progression or death by 30% in certain NSCLC patients.

Liquidia (LQDA) Down on FDA Delaying Full Approval for Yutrepia

by Zacks Equity Research

The FDA grants tentative approval to Liquidia's (LQDA) inhaled powder for two lung disorder indications. Full approval may be granted after May 2025, when the regulatory exclusivity of a competing product expires.

AbbVie (ABBV) Gets Nod in EU for Lymphoma Drug's Expanded Use

by Zacks Equity Research

AbbVie's (ABBV) Tepkinly gets conditional approval in the EU to treat third-line patients with relapsed or refractory follicular lymphoma as a second indication.

AN2 Therapeutics (ANTX) Plunges 66% in a Month: Here's Why

by Zacks Equity Research

AN2 Therapeutics (ANTX) falls 66% in a month after terminating its mycobacterium avium complex lung disease study of epetraborole due to unsatisfactory efficacy results.

FDA Expands AstraZeneca's (AZN) Imfinzi Label in Lung Cancer

by Zacks Equity Research

This approval is based on late-stage study data, which shows that treatment with AstraZeneca's (AZN) Imfinzi reduced the risk of recurrence by 32% in certain non-small cell lung cancer patients.

Arcturus Therapeutics (ARCT) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of 65.41% and 137.42%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?